TRexBio, an Eli Lilly–backed company focused on immunology, has priced its initial public offering (IPO) to raise about $117 million. The company is developing therapies intended to treat immunological conditions by activating regulatory T (“Treg”) cells, a target area described by multiple outlets in connection with its drug pipeline.
The IPO is priced at $14 per share and is listed on the Nasdaq exchange, according to outlet reports. BioPharma Dive also notes that Eli Lilly is the largest equity holder in TRex, underscoring the degree of backing the company has from a major pharmaceutical player. Other coverage focuses primarily on deal terms—namely the pricing and the size of the offering—rather than expanded details of the technology or pipeline.
Across the sources, there is agreement on the headline figures: the per-share price, the total amount expected to be raised, and the Nasdaq listing, with BioPharma Dive providing additional context about Eli Lilly’s role and the Treg-based therapeutic approach.
